BenevolentAI, a leading clinical-stage company, is revolutionizing the field of drug discovery and development with its innovative use of artificial intelligence. The company’s proprietary Benevolent Platform is an experimental drug discovery platform that leverages AI technologies to find new medicines for several serious diseases, including Parkinson’s disease.

The platform focuses on three key areas: Target Identification, Molecular Design, and Precision Medicine. It is disease agnostic, meaning it can be applied to any disease and is capable of rapidly generating novel targets at scale. This allows BenevolentAI to uncover potential treatments in record time. For instance, the company was able to identify baricitinib as a possible treatment for coronavirus in just 90 minutes of computing time and three days of work.

BenevolentAI’s approach has proven to be significantly faster than traditional drug discovery methods. In just four years, the company has produced 24 drug candidates. Furthermore, BenevolentAI has the capability to identify molecules that have failed in clinical trials and predict how these same compounds can instead be more efficient targeting other diseases.